Back

Eligibility for dapagliflozin and empagliflozin in real-world heart failure based on DAPA-HF, DELIVER, EMPEROR-Reduced and EMPEROR-Preserved selection criteria

29 June 2021 (08:00 - 08:00)
Organised by:
Congress Presentation Part of: Registry Updates Pharmacotherapy HFA Premium Access Heart Failure 2021

About the speaker

Photo
Professor Gianluigi Savarese

Karolinska Institute, Stockholm (Sweden)

10 More presentations in this session

Presentation thumbnail
SCD and ventricular event rates in a Japanese population: Primary results from the Heart Failure Indication and Sudden Cardiac Death Prevention Trial
Doctor K. Aonuma (Tsukuba, JP)
Slides Video
Presentation thumbnail
Clinical course and related costs of patients with type 2 diabetes and heart failure and/or chronic kidney disease, drawn from a sample of more than 7 million people
Doctor A. Maggioni (Florence, IT)
Slides Video
Presentation thumbnail
Potential Implications of Expanded FDA Labeling for Sacubitril/Valsartan in the United States
Doctor M. Vaduganathan (Boston, US)
Slides Video
Presentation thumbnail
Prescription Fill Patterns of Guideline-Directed Medical Therapies for Heart Failure During the COVID-19 Pandemic in the United States
Doctor M. Vaduganathan (Boston, US)
Slides Video
Presentation thumbnail
Higher Alkaline Phosphatase Mean and Variability Predict Heart Failure and All-cause Mortality
Ms S. Lee (Hong Kong, CN)
Slides Video

Access the full session

Session thumbnail
Registry Updates

The Event

Event poster

Heart Failure 2021

29 June 2021 08:00 CET
You may be interested in
thumbnail
Congress Presentation
Real-world eligibility for dapagliflozin in unselected heart failure patients: data from the CORDIS-HF registry
29 June 2021
thumbnail
Congress Session
Advances in medical therapy in heart failure
20 May 2025
thumbnail
Congress Presentation
Similarities and differences between SGLT2i trials in HFpEF
24 May 2022
thumbnail
Congress Presentation
Benefits of empagliflozin in Hispanics and non-Hispanics with heart failure: a sub-analysis of the EMPEROR-trials
20 May 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources